BBI-2000

Phase 1Small molecule

FFresh Tracks Therapeutics, Inc.

BBI-2000 is one of 19 small molecule programs targeting Contact Dermatitis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Contact DermatitisActive, not recruiting

Contact DermatitisPhase 1

Active, not recruiting

Competition

Competitive Landscape

20 competitors in Contact Dermatitis

#DrugCompanyPhaseTrials

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Rayos

Decadron

AAspen Global Incorporated

Stelara

1 5

Ilaris

Novartis

Phase 3

1 6

Tremfya

Johnson & Johnson

Phase 3

1 7

Flovent

GSK

Phase 3

1 8

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 9

Kevzara

AAzienda U.S.L. 1 di Massa e Carrara

Phase 3

1 10

Humira

CCelltrion

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Contact Dermatitis1 trial

Evaluation of Safety and Efficacy of BBI-2000 in Treating and Preventing Contact Dermatitis

Completed·FFresh Tracks Therapeutics, Inc.·Phase 1·NCT03089775·47 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BBI-2000. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BBI-2000 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BBI-2000. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fresh Tracks Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: FFresh Tracks Therapeutics, Inc.

BBI-2000

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Contact Dermatitis1 trial

References

Drug Info

Quick Facts

Related News